艾伯维12亿美元押注三抗TCE，与泽璟达成合作和授权协议

Minhua笔记01-01

12月31日，艾伯维宣布与苏州泽璟生物制药达成合作和授权许可协议，总价值最高12亿美元，包括1亿美元预付款、最高6000万美元近期临床和选择权付款，以及若行使选择权后最高10.75亿美元开发、注册和销售里程碑付款，外加中国以外销售的分级特许权使用费（高个位数至中双位数百分比）。艾伯维获得ZG006（alveltamig）中国以外全球独家开发和商业化权益；泽璟制药保留中国的全部权益。ZG006为靶向...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2600118059?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-01 15:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2600118059","market":"us","top_or_hot":-1,"title":"艾伯维12亿美元押注三抗TCE，与泽璟达成合作和授权协议","media":"Minhua笔记","content":"<div>\n<p>12月31日，艾伯维宣布与苏州泽璟生物制药达成合作和授权许可协议，总价值最高12亿美元，包括1亿美元预付款、最高6000万美元近期临床和选择权付款，以及若行使选择权后最高10.75亿美元开发、注册和销售里程碑付款，外加中国以外销售的分级特许权使用费（高个位数至中双位数百分比）。艾伯维获得ZG006（alveltamig）中国以外全球独家开发和商业化权益；泽璟制药保留中国的全部权益。ZG006为靶向...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾伯维12亿美元押注三抗TCE，与泽璟达成合作和授权协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾伯维12亿美元押注三抗TCE，与泽璟达成合作和授权协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-01 15:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b><strong>Minhua笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月31日，艾伯维宣布与苏州泽璟生物制药达成合作和授权许可协议，总价值最高12亿美元，包括1亿美元预付款、最高6000万美元近期临床和选择权付款，以及若行使选择权后最高10.75亿美元开发、注册和销售里程碑付款，外加中国以外销售的分级特许权使用费（高个位数至中双位数百分比）。艾伯维获得ZG006（alveltamig）中国以外全球独家开发和商业化权益；泽璟制药保留中国的全部权益。ZG006为靶向...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0004445239.USD","symbol_name":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b","article_id":"2600118059","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2600118059","pubTimestamp":1767252148,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"艾伯维正通过一项可能高达12亿美元的交易，进一步拓展其在肿瘤免疫治疗领域的布局。该交易包括向泽璟支付1亿美元的首付款，以及高达6000万美元的近期临床和选择权相关款项。艾伯维在2025年通过两项以三特异性抗体为核心的交易，进一步丰富了其肿瘤产品线。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4139":"生物科技","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4559":"巴菲特持仓","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4550":"红杉资本持仓","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","ABBV":"艾伯维公司","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC"},"translate_title":"AbbVie's $1.2 billion bet on tertiary antibody TCE, reaches cooperation and licensing agreement with Zejing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9},"content_text":"12月31日，艾伯维宣布与苏州泽璟生物制药达成合作和授权许可协议，总价值最高12亿美元，包括1亿美元预付款、最高6000万美元近期临床和选择权付款，以及若行使选择权后最高10.75亿美元开发、注册和销售里程碑付款，外加中国以外销售的分级特许权使用费（高个位数至中双位数百分比）。艾伯维获得ZG006（alveltamig）中国以外全球独家开发和商业化权益；泽璟制药保留中国的全部权益。ZG006为靶向DLL3的三特异性T细胞衔接器。目前推进多项试验，包括复发SCLC III期（对比研究者选择化疗）、一线ES-SCLC联合PD-1/PD-L1 I期（12月启动）、神经内分泌前列腺癌 II期（今年夏季启动）。这是艾伯维2025年第三笔三特异性抗体交易，前两笔分别为7月19亿美元许可IGI Therapeutics ISB 2001（BCMA/CD38/CD3，用于多发性骨髓瘤）和年初与先声再明合作SIM0500（多发性骨髓瘤I期）。艾伯维正通过一项可能高达12亿美元的交易，进一步拓展其在肿瘤免疫治疗领域的布局。该交易将使艾伯维有可能获得泽璟制药开发的三特异性T细胞衔接器ZG006（alveltamig）在中国以外地区的全球权益。该交易包括向泽璟支付1亿美元的首付款，以及高达6000万美元的近期临床和选择权相关款项。如果艾伯维行使授权许可的选择权，且该药物研发进展顺利，泽璟有望获得高达10.75亿美元的额外开发、监管和销售里程碑付款，以及除中国以外地区销售额的分级特许权使用费，费率从个位数高位到两位数中位不等。泽璟保留在中国的全部开发和商业化权利。ZG006靶向DLL3蛋白，该蛋白在小细胞肺癌（SCLC）和神经内分泌肿瘤中高表达，同时募集T细胞攻击恶性细胞。该药目前正在进行多项临床试验，包括一项针对复发性SCLC的III期研究，该研究将ZG006与研究者选择的化疗方案进行比较；一项于去年12月启动的与PD-1/PD-L1抑制剂联合用药、针对广泛期SCLC的一线治疗的I期研究；以及一项于今年夏季启动的针对神经内分泌前列腺癌的II期研究。艾伯维在2025年通过两项以三特异性抗体为核心的交易，进一步丰富了其肿瘤产品线。今年7月，该公司签署了一项价值19亿美元的授权许可协议，获得IGI Therapeutics开发的用于治疗多发性骨髓瘤的BCMA/CD38/CD3三特异性抗体ISB 2001（现也称为ABBV-2001）的授权。今年早些时候，艾伯维还与先声药业合作开发了SIM0500，这是另一款用于治疗多发性骨髓瘤的三特异性抗体候选药物，目前正在美国和中国进行I期临床试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600118059","isCrawlerRequest":true}